AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05236413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension (DASH) Diet
Description: Patients will be interviewed with regard to their food/religious preferences and food allergies and a 7-day rotating meal plan will be designed per their preferences along with a registered dietitian. This will ensure that patients receive food that is acceptable to them. Participants will then be provided pre-packaged meals for 4-weeks with macronutrient compositions as follows - (Carbohydrates -55-60%, Protein -15-20%, Fat -15-25%, Fiber -35-45g/day). All foods will be labeled, sealed, and packed for weekly delivery and will be designed such that they can be refrigerated or frozen and stored without significant alterations to nutritional content. All food will be prepared by the UVA Hospital Nutrition Services department in conjunction with a registered dietician. Deviations (if any) from the study meal plan will be recorded by the participants in a food record provided at the start of each diet intervention period.
Study NCT05236413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + DASH Diet
Description: Patients will undergo both the exercise training intervention and DASH diet as explained above.
Study NCT05115409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Antibody Plus Chidamide and Rituximab
Description: Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks
Study NCT05842460 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrient warning labels
Description: Inclusion of nutrient warning labels, which are currently mandatory in Brazil, to images of food products.
Study NCT05842460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrient and ultraprocessed warning labels
Description: Inclusion of nutrient warning labels, which are currently mandatory in Brazil, and an experimental ultraprocessed warning label to images of food products.
Study NCT05000489 — intervention group
Intervention type: OTHER
Intervention: No intervention being administered
Description: No intervention will be administered. Each patient will participate in a qualitative focus group discussing their beliefs/attitudes about their reproductive health and birth control
Study NCT04946955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application and website with or without promotion
Description: Development of an application and a website to de-stigmatise mental health and support the user in seeking help
Study NCT04946955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Application and website with or without promotion
Description: Development of an application and a website to de-stigmatise mental health and support the user in seeking help
Study NCT04102436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study NCT04102436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Study NCT04102436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg or 72,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
Study NCT04102436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sleeping Beauty Transposed PBL
Description: Day 0: Cells are to be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes or as clinically determined by an investigator for patient safety (between 2-4 days after the last dose of fludarabine).
Study NCT05690061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grain-Fed Beef Hamburger
Description: Bowl of grain-fed beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
Study NCT05690061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grass-Fed Beef Hamburger
Description: Bowl of grass-fed, grass-finished beef hamburger cooked without seasonings. 250 grams of uncooked hamburger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
Study NCT05690061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Impossible BurgerTM
Description: Bowl of plant-based Impossible burger cooked without seasonings. 250 grams of uncooked Impossible burger weighed out, then cooked in a non-stick pan for 8 minutes, no seasoning or oils were used and rendered fat was poured into serving bowl.
Study NCT05761145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection
Study NCT05443087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling to build population pharmacokinetics model
Description: Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~* 1 month after the first treatment administration~* 2 months after the first treatment administration~* In case of progression~* In case of severe toxicities (AESI) related to the drug received
Study NCT06431399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-2004 qd
Description: Group I(Peroid I-JLP-2004 FAST, Peroid II-JLP-2004 FED), Group II(Period I-JLP-2004 FED, Period II-JLP-2004 FAST)
Study NCT04810494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine HCl topical solution
Description: 0.5mL of 2% Lidocaine will be administered intranasally in each nostril with a mucosal atomization device.
Study NCT04810494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium chloride
Description: 0.5mL of 0.9% Sodium chloride (normal saline) will be administered intranasally in each nostril with a mucosal atomization device.
Study NCT06029933 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
Description: Fluad Quadrivalent vaccine is an inactivated influenza vaccine formulated to contain 60 mcg of hemagglutinin (HA) total, with 15 mcg from each of the four recommended influenza strains and the MF59 adjuvant in single-dose prefilled 0.5 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluad as part of routine clinical care during the influenza season.
Study NCT06029933 — intervention group
Intervention type: BIOLOGICAL
Intervention: High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Description: Fluzone High-Dose Quadrivalent vaccine is an inactivated split virion influenza vaccine formulated to contain 240 mcg of HA total, with 60 mcg from each of the four recommended influenza strains in single-dose prefilled 0.7 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluzone High-Dose as part of routine clinical care during the influenza season.
Study NCT05321706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 mg
Description: Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin
Study NCT05321706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.
Study NCT01025934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT01025934 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Study NCT04845035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: By mouth
Study NCT04845035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: By mouth
Study NCT04845035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berlin-Frankfurt-Münster Chemotherapy
Description: with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin, Thioguanine, and Dexamethasone
Study NCT04845035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate and Cytarabine
Description: Intrathecal
Study NCT05763992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)
Description: Each FLA cycle will consist of 5 consecutive days of a specific FLA scheme, which will be repeated with a three-week interval. The FLA will consist of a plant-based, low-calorie (about 600 Kcal on day 1; about 300 Kcal on day 2 to 5), low-protein, low-carbohydrate diet. The first FLA cycle will start two days prior to the day of first chemo-immunotherapy cycle administration and will continue for two more days after chemotherapy. In the absence of significant contraindications or severe adverse events, subsequent FLA cycles will recur with three-week intervals and will maintain the same timing with respect to chemo-immunotherapy administration.
Study NCT05763992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)
Description: Each FLA cycle will consist of 5 consecutive days of a specific FLA scheme, which will be repeated with a three-week interval. The FLA will consist of a plant-based, low-calorie (about 600 Kcal on day 1; about 300 Kcal on day 2 to 5), low-protein, low-carbohydrate diet. The first FLA cycle will start two days prior to the day of first chemo-immunotherapy cycle administration and will continue for two more days after chemotherapy. In the absence of significant contraindications or severe adverse events, subsequent FLA cycles will recur with three-week intervals and will maintain the same timing with respect to chemo-immunotherapy administration.
Study NCT05951725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP)
Description: Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
Study NCT05951725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP
Description: Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
Study NCT05951725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib
Description: Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
Study NCT05951725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTcP
Description: Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
Study NCT05951725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV-Hib
Description: Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
Study NCT05951725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTcP
Description: Three doses of basic immunization were completed at 2, 4 and 6 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
Study NCT05282849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided fascia iliaca block
Description: ultrasound guided fascia iliaca block anesthetizes variable combinations of the femoral nerve , lateral femoral cutaneous nerve , and obturator nerve, and is effective for many painful hip surgeries making it potentially useful for analgesia following Developmental Dysplasia of Hip (DDH) surgery.
Study NCT05282849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided quadratus lumborum block
Description: ultrasound-guided quadratus lumborum (QL) block provides perioperative somatic, even visceral analgesia for patients including pediatrics, undergoing abdominal or hip surgery. The local anesthetic injected adjacently into the quadrates lumborum muscle spreads in a medial and cranial direction under the crura and arcuate ligaments of the diaphragm, then into the thoracic paravertebral space anesthetizing the hip region
Study NCT06487819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of a rubber dam during dental treatments for varying durations.
Description: Patients in each group will undergo dental procedures (either operative or endodontic treatment) with rubber dam isolation. The rubber dam will be applied for the specific durations mentioned in each group to evaluate the impact of mouth opening on the temporomandibular joint (TMJ).
Study NCT05518760 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04572256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
Study NCT04572256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral placebo will be taken daily for 6 months post surgery.
Study NCT06004596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 13C-Spirulina Gastric Emptying Breath Test (GEBT)
Description: Diagnostic test
Study NCT06004596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C-Spirulina Gastric Emptying Breath Test (GEBT)
Description: Diagnostic test
Study NCT06004596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 13C-Spirulina Gastric Emptying Breath Test (GEBT) - repeat
Description: Diagnostic test - repeat for biological variability deterination
Study NCT04810039 — intervention group
Intervention type: OTHER
Intervention: Predict the outcome of the Glasgow Outcome Scale
Description: Predict the outcome of the Glasgow Outcome Scale (GOS) score at 6 months compared to the actual outcome, in 20 anonymized records.
Study NCT05494229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pars-plana vitrectomy
Description: Pars-plana vitrectomy
Study NCT05251363 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Solia S lead
Description: The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.
Study NCT06473597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant
Description: NURTEC ODT 75 mg orally disintegrating tablets
Study NCT06473597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan Benzoate
Description: Rizatriptan ODT 10mg orally disintegrating tablets
Study NCT05814094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusion
Description: Following randomisation, if a patient's Hb concentration reads ≤ 70g/L, one unit of RBC will be transfused within 12 hours of the result becoming available. Additional units can be prescribed if required to raise the Hb concentration to above 70g/L. A transfusion above the restrictive threshold of 70g/L is discouraged.
Study NCT05814094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusion
Description: Following randomisation, if a patient's Hb concentration reads ≤ 90g/L, one or more units of RBC will be transfused in order to raise the Hb concentration to greater than 90g/L within 12 hours of the result becoming available. A decision not to transfuse below the threshold of 90g/L is discouraged.
Study NCT05756790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Counseling
Study NCT05756790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus Breathalyzer
Description: Counseling plus mobile breathalyzer/ app
Study NCT05554913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911
Description: This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
Study NCT05554913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT05306782 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Electrical Stimulation
Description: transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).
Study NCT05306782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Electrical Stimulation
Description: transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).
Study NCT05306782 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Speech Therapy
Description: Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes
Study NCT05306782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Therapy
Description: Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes
Study NCT06579183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Strength VitaJoy (ES/VJ)
Description: Extra Strength VitaJoy Capsule, 2 capsules in the morning
Study NCT06579183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Strength Vita Calm (ES/VC)
Description: Extra Strength Vita Calm Capsule, 2 capsules in the evening
Study NCT06579183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule, 4 capsules in the morning and evening respectively
Study NCT04754438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: Electronically delivered cognitive behavioural therapy
Study NCT04754438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health Coaching
Description: Electronically delivered mental health coaching
Study NCT06126835 — intervention group
Intervention type: DRUG
Intervention: Ozanimod
Description: Women with UC exposed to ozanimod during pregnancy
Study NCT06126835 — intervention group
Intervention type: DRUG
Intervention: Conventional therapy
Description: Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy
Study NCT06126835 — intervention group
Intervention type: DRUG
Intervention: Advanced therapy
Description: Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy
Study NCT06433661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: Participants will receive single dose of oral Etavopivat in each treatment period.
Study NCT05669430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GV20-0251
Description: Increasing doses of GV20-0251 administered by intravenous (IV) infusion once or twice every 3 weeks as monotherapy.
Study NCT05669430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GV20-0251
Description: GV20-0251 preliminary RP2D administered by IV infusion as monotherapy.
Study NCT05669430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GV20-0251 and Pembrolizumab [KEYTRUDA®]
Description: GV20-0251 administered by IV infusion at 10 mg/kg once every 3 weeks or at increasing doses up to the preliminary RP2D determined in Part A. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
Study NCT05669430 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GV20-0251 and Pembrolizumab [KEYTRUDA®]
Description: GV20-0251 administered by IV infusion at preliminary RP2D from Part C. 200 mg pembrolizumab administered by IV infusion once every 3 weeks.
Study NCT04984473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure
Study NCT04984473 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training for 12 weeks at 40% maximal inspiratory pressure
Study NCT06320431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Thrombolytic